Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arbutus Biopharma Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ABUS
Nasdaq
2836
www.arbutusbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arbutus Biopharma Corporation
Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
- Nov 13th, 2026 3:14 am
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
- Nov 13th, 2026 2:11 am
Arbutus: Q3 Earnings Snapshot
- Nov 10th, 2026 5:36 am
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Nov 10th, 2026 5:30 am
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises
- Nov 6th, 2026 10:00 am
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
- Oct 22nd, 2026 5:30 am
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
- Oct 1st, 2026 5:30 am
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
- Sep 30th, 2026 5:30 am
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
- Aug 24th, 2026 5:30 am
Sector Update: Healthcare Stocks Advance in Afternoon Trading
- Aug 21st, 2026 11:43 am
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
- Aug 21st, 2026 7:32 am
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
- Aug 21st, 2026 6:56 am
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
- Aug 21st, 2026 5:30 am
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
- Aug 20th, 2026 5:35 am
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Aug 12th, 2026 5:30 am
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
- Aug 10th, 2026 6:18 pm
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
- Jul 31st, 2026 12:04 pm
Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside
- Jul 22nd, 2026 3:08 pm
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
- Jul 20th, 2026 9:09 am
Scroll